Aktiesnakken — Juli 2010
-
Sydbanks vurdering af GEN
http://npinvestor.dk/nyheder/sydbank-genmab-er-en-overskudsforretning-i-2013-207921.aspx -
de fordeler aftalen lineært ligesom os
-
jeg er imponeret over at de kan veksle 500K hernede
-
bare det ikke er PI´ere så er jeg ligeglad
-
-
-
- Hvis du tror på Arzerra, bør du tro på selskabet, fordi vi i den nye aftale var i stand til at beholde de fulde royalties inden for cancerindikationer. Det er meget væsentligt for den fremtidige vækst. Jeg vil ikke nu fortælle dig, at vi til augus
-
yes Jan!
-
-
her er den fra Direkt http://borsen.dk/vaerktoejer/virksomhedsside/artikel/direct/2/179954.html
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind